Clinical Trials · NCT02472717
Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study
- Phase
- Phase 2
- Recruitment status
- Withdrawn
- Sponsor
- University Health Network, Toronto
- Enrollment
- 0
- Start date
- May 2015
- Locations
- 1 site, Canada
- Primary endpoint
- The change in the proportion of patients achieving an ACR 20% improvement response in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to placebo